HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

KR36676

a urotensin receptor antagonist

Also Known As:

2-(6,7-dichloro-3-oxo-2H-benzo(b)(1,4)oxazin-4(3H)-yl)-N-methyl-N-(2-(pyrrolidin-1-yl)-1-(4-(thiophen-3-yl)phenyl)ethyl)acetamide

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Amides: 2428
  - Acetamides: 21
    - KR36676: 2
- Carboxylic Acids: 973
  - Acyclic Acids
    - Acetates: 4994
      - Acetamides: 21
        KR36676: 2
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Oxazines: 9
    - Benzoxazines: 58
      - KR36676: 2
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Benzoxazines: 58
      - KR36676: 2

Experts

1.	Lee, Byung Ho: 1 article (11/2016)
2.	Lee, Jeong Hyun: 1 article (11/2016)
3.	Lim, Chae Jo: 1 article (11/2016)
4.	Oh, Kwang-Seok: 1 article (11/2016)
5.	Park, Byung Kil: 1 article (11/2016)
6.	Seo, Ho Won: 1 article (11/2016)
7.	Yi, Kyu Yang: 1 article (11/2016)
8.	Lee, B H: 1 article (05/2015)
9.	Lee, J H: 1 article (05/2015)
10.	Lee, S: 1 article (05/2015)

Related Diseases

1.	Hypertrophy 05/01/2015 - "U-II-induced stress fibre formation and cellular hypertrophy were significantly inhibited with low concentrations of KR36676 (≥0.01 μM). " 11/01/2016 - "Oral administration of KR36676 effectively decreased the MCT-induced increase in right ventricular systolic pressure, hypertrophy and fibrosis. " 05/01/2015 - "Pharmacological properties of KR36676 were studied in a range of in vitro assays (receptor binding, calcium mobilization, stress fibre formation, cellular hypertrophy) and in vivo animal models such as cardiac hypertrophy induced by transverse aortic constriction (TAC) or myocardial infarction (MI). "
2.	Fibrosis (Cirrhosis) 11/01/2016 - "Oral administration of KR36676 effectively decreased the MCT-induced increase in right ventricular systolic pressure, hypertrophy and fibrosis. " 05/01/2015 - "Oral administration of KR36676 (30 mg·kg(-1) ) in a TAC model in mice attenuated cardiac hypertrophy and myocardial fibrosis. "
3.	Vascular Remodeling 11/01/2016 - "The novel UT antagonist, KR36676, effectively prevented MCT-induced PAH progression and pulmonary vascular remodeling in rat model. " 11/01/2016 - "A urotensin II receptor antagonist, KR36676, decreases vascular remodeling and inflammation in experimental pulmonary hypertension."
4.	Myocardial Infarction 05/01/2015 - "Pharmacological properties of KR36676 were studied in a range of in vitro assays (receptor binding, calcium mobilization, stress fibre formation, cellular hypertrophy) and in vivo animal models such as cardiac hypertrophy induced by transverse aortic constriction (TAC) or myocardial infarction (MI). "
5.	Inflammation (Inflammations) 11/01/2016 - "A urotensin II receptor antagonist, KR36676, decreases vascular remodeling and inflammation in experimental pulmonary hypertension."

Related Drugs and Biologics

1.	Urotensins
2.	Calcium
3.	urotensin II

Related Therapies and Procedures

1.	Oral Administration